Upfront Payments in Biotech Deals by Therapeutic Category
This month, we compared upfront payments in biotech deals signed at the R&D or preclinical phase of development by therapeutic category. These deals tend to be weighted more towards equity purchases. Here we've graphed these payments starting in1991 through June 1996.
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.